ReviewEuropean journal of clinical pharmacology2026
Artificial intelligence and machine learning for precision warfarin dosing: a comprehensive narrative review.
Review in European journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Machine learning to identify novel bleeding and residual thromboembolic risks in patients on anticoagulation.Journal of thrombosis and thrombolysis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWarfarin remains one of the most widely used anticoagulants; however, its narrow therapeutic index means that even small dosing deviations can result in thromboembolic or bleeding events, necessitating close monitoring and strict control of the international normalized ratio (INR). MAIN BODY: Although traditional warfarin dosing algorithms incorporating CYP2C9 and VKORC1 genotypes improve upon fixed-dose regimens, they explain less than 50% of dose variability and perform inconsistently across populations. These limitations underscore the need for more adaptive and precise dosing methodologies. Artificial intelligence (AI) and machine learning (ML) have been recognized as powerful approaches to advance warfarin dose individualization. This narrative review synthesizes literature on machine learning approaches to warfarin dosing, including support vector regression, neural networks, ensemble models, and reinforcement learning, with a focus on predictive performance and clinical relevance. Overall, the literature indicates that ML-based warfarin dosing models may improve prediction of the therapeutic warfarin dose and regulation of INR levels compared with traditional clinical and pharmacogenetic interventions. However, many published models are constrained by small sample sizes and limited external validation, reducing generalizability. Methodological heterogeneity and inconsistent reporting further underscore persistent gaps in the evidence base.
conclusionAI and ML approaches have shown potential advantages over clinical and pharmacogenetic dosing methods for warfarin, with some studies reporting lower prediction errors and improved therapeutic INR control. However, further studies are needed to draw definitive conclusions about their comparative effectiveness.
Indexed as
Identifiers
41649565What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.